Analyzing MediWound (MDWD) & The Competition

MediWound (NASDAQ: MDWD) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare MediWound to similar businesses based on the strength of its profitability, earnings, dividends, risk, institutional ownership, valuation and analyst recommendations.


This table compares MediWound and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
MediWound -752.78% -326.32% -48.65%
MediWound Competitors -13,997.42% 58.52% -18.87%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MediWound and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MediWound 0 0 5 0 3.00
MediWound Competitors 121 766 1637 59 2.63

MediWound presently has a consensus target price of $10.00, indicating a potential upside of 100.00%. As a group, “Biopharmaceuticals” companies have a potential upside of 11.74%. Given MediWound’s stronger consensus rating and higher possible upside, equities research analysts clearly believe MediWound is more favorable than its competitors.

Earnings & Valuation

This table compares MediWound and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
MediWound $2.17 million -$16.18 million -6.67
MediWound Competitors $579.41 million $241.76 million -7.09

MediWound’s competitors have higher revenue and earnings than MediWound. MediWound is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

19.5% of MediWound shares are held by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

MediWound has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, MediWound’s competitors have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.


MediWound competitors beat MediWound on 8 of the 12 factors compared.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with's FREE daily email newsletter.

Leave a Reply